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ABSTRACT 
         
         BACKGROUND:       
The prevalence of lithium induced skin reactions ranges from 3- 45% in various studies. 
Cutaneous side effects occurs when the dose of lithium 800-1200, on therapeutic level 
(0.8 -1.2meq/l) and when lithium is given for the longer duration (more than 1 year). 
 
OBJECTIVES OF THE STUDY: 
1. To assess the prevalence of skin reactions in Bipolar affective disorder (BPAD) 
patients on lithium 2.To evaluate the relationship between the dosage of lithium and 
cutaneous side effects 3.To assess the relationship between serum lithium level and 
cutaneous side effect. 4.To evaluate the duration of lithium therapy and cutaneous 
side effects.5.To assess the reduction or stoppage of dose of lithium has any change 
in the course of cutaneous side effects.6.To assess the course of pre-existing skin 
reactions, when patient is initiated on lithium therapy. 
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METHODOLOGY:  
Prospective observational study. Both Inpatient and outpatients with bipolar affective 
disorder on lithium therapy were recruited. They were assessed with initial semi-
structured proforma and dermatologist opinion obtained for patients who developed 
cutaneous side effects. They were followed up for once  a month for 6 months and once 
in 2 months thereafter for 1 year. 
RESULT:   
 The prevalence of lithium induced skin reactions was 38.46%. .Our study has shown 
different dosage and serum lithium level doesn’t correlate statistically with lithium 
induced skin reaction but longer the duration more is the chance for lithium induced 
cutaneous side effects. 
 
CONCLUSION:  
Prevalence of Lithium induced skin lesions continues to be high. Clinician should 
educate the patient before initiating lithium to improve the attrition rate. Prevalence 
doesn’t vary between the dosage and serum lithium level, but varies with duration of 
lithium therapy. Hence, the clinician need not be ambivalent about reducing the dose but 
should be cautious on prolonged treatment. 
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INTRODUCTION: 
Lithium has been used in the treatment of mood disorders for more than five decades. Inspite of 
its narrow therapeutic index and multiple systemic side effects lithium remains the golden 
standard treatment for bipolar affective disorder. Various studies have been done to find the 
relationship between the dose of lithium carbonate, serum lithium levels, duration of therapy, and 
clinical response.  
Lithium is a cheaper and easily available molecule compared to other mood stabilizers approved 
by Food and drug administration (FDA). Apart from its mood stabilizing effect it’s preferable 
among mood stabilizer for its anti-depressant and anti-suicidal properties. 
 
The dosage of lithium therapy is individualized. It is usually started with the low divided doses 
and is titrated up based on the serum lithium levels to minimize the side effects. Serum lithium 
level is monitored once a week until a concentration of 0.8-1.2meq/l is reached. (1) Inspite of 
recommended maintenance of lithium considered being 0.5-0.8 meq/l; it is preferable to continue 
the same dose of lithium that was considered for acute episode.  
 
Previous studies has recommended a therapeutic range from 0.7 to1.2 meq/l as Lithium was 
found to be ineffective at levels below 0.9meq/l.  They also have reported that no therapeutic 
advantage was noted when the serum lithium level is above 1.3meq. But with levels more than 
1.4meq/l there were severe side effects (2). In previous studies Lithium induced cutaneous side 
effects occurred mostly within therapeutic range and few above the therapeutic range (3, 4).  
15 
 
 
With the lithium level of 1.5-2meq/l mild to moderate intoxication occurs characterized by 
gastrointestinal symptoms like vomiting abdominal pain, dryness of mouth, and neurological 
symptoms are ataxia, dizziness, slurred speech, nystagmus, lethargy or excitement and muscle 
weakness. 
Serum lithium levels between 2 to 2.5 meq/l can cause moderate to severe intoxication 
characterized by blurred vision, muscle fasciculation, clonic limb movement, hyperactive deep 
tendon reflex, choreoathetoid movements, convulsion, delirium, syncope, stupor, coma and 
circulatory failure (low BP, cardiac arrhythmias and conduction abnormalities). GI symptoms 
like anorexia and persistent vomiting. 
Severe lithium intoxication occurs with the level > 2.5meq/l characterized by generalized 
convulsion, oliguria, renal failure and death (5). > 4meq/l intoxication requires dialysis as 
treatment. 
 Few studies have shown that even lower lithium levels (0.4-0.6meq/l), can cause cutaneous side 
effects compared to therapeutic range (3).   
 
 Studies have shown that longer the duration of Lithium therapy, more is the chance of 
developing side effects (4, 9). However skin reaction may occur as early as within few days of 
starting Lithium therapy.  
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Lithium has been the focus of numerous investigations for its side-effects. Most of the studies 
were concerned with the systemic side effects like hypothyroidism, hyperthyroidism, 
hyperparathyroidism, nephrogenic diabetic insipidus, nephritic syndrome, renal tubular acidosis, 
cardiac bradyarrhythmia, heart block, tremors, diarrhoea and convulsions. Though Lithium is 
notorious to cause cutaneous lesions (6) the literature on skin disorders secondary to lithium 
therapy is limited. 
 
Lithium is known to cause multiple cutaneous side effects. The most common cutaneous side 
effects associated with lithium are acneiform eruptions and psoriasiform eruption (8). It has been 
known to cause psoriasis and also exacerbate the pre-existing psoriasis .It causes specific 
manifestations like acneiform eruptions, seborrheic dermatitis, and follicular keratitis.  
 
 
Other cutaneous manifestations includes mucosal and vaginal ulceration,  oedema, purpura, 
lupus erythematosis like syndrome, urticaria, pre-tibial ulceration,dermatitis herpetiformis, 
eczema, exfoliative dermatitis,  folliculitis, alopecia, allergic vasculitis, hidradenitis suppurativa, 
lichenoid stomatitis, exacerbation of Darrier’s disease,  palmoplantar hyperkeratosis with 
icthyosiform features, increased growth of wart, mycosis fungoidosis,  increased growth of warts 
and hair loss(7,9). 
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In previous study, females showed increased incidence of cutaneous side effects compared to 
males (8). In other study secondary cutaneous side effects are more common with males (8).The 
most distressing lithium induced cutaneous side effects being psoriasis and it has been associated 
with the increased risk of suicide and substance use .These disturbances in the self image affects 
their social, occupational and interpersonal functioning. This may contribute to the risk of non-
compliance among lithium treated patients (10). 
 
The prevalence of lithium induced skin reactions is reported to range from 3 to 34 %( 8). In 
another study the prevalence of lithium induced skin reactions is reported to be 45 %( 9). There 
are very few studies on lithium induced skin reactions and chances of discontinuation of therapy 
because of adverse skin reactions persist in clinical settings.  
 
We did a pilot project retrospectively based on the case records with sample of 30 BPAD 
patients where the prevalence of lithium induced skin reaction was 20% .We had concluded that 
higher the dose of lithium increase in the prevalence of skin reaction. The prevalence was also 
high in sub-therapeutic (0.5-0.8meq/l) serum lithium level. 
 
Hence we planned to do a prospective observational study and are unique of its kind as there is 
no published study on the relationship between cutaneous side effect with lithium dosage, 
duration and serum lithium level.  
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REVIEW OF LITERATURE: 
There is a paucity of literature on lithium induced skin reactions. Most common conditions seen 
with lithium therapy are acne and psoriasis. 
 
Lithium and maculopapular eruptions: 
Maculopapular eruption is a type of rash characterized by an erythematous spot with small, flat 
red area covered raised bumps. 
Callaway et al in 1968 had reported 5 cases of lithium induced maculopapular eruptions. Of 
which three had developed lesions in the whole body and one had developed in the legs. Three 
had pre-tibial ulceration and 3 were associated with pruritis. (11) All occurred within 3 weeks of 
duration of lithium therapy and with the levels of 0.53-1.5meq/l. maculopapular eruptions and 
cutaneous ulcers were cleared after discontinuation of lithium in 2 cases and after reduction of 
dosage with the treatment of topical applicants in other case 
 
Posey had described a case that had developed pruritic papular dermatitis on pressure point in 
young female. These lesions resemble dermatitis herpetitiformis.  It resolves when the dose of 
lithium is tapered to the lithium level of 0.8-1.2 meq/l and on treatment with sodium sufoxone(12). 
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Meinhold et al had described a diffuse, erythematous maculopapular rash in volunteers with no 
past episode of any dermatological complaints or allergies. It occurs with the dose of 600mg of 
lithium on two different occasions (13). 
 
In general lithium induced maculopapular eruptions are generalized and pruritic and it occurs 
due to delayed hypersensitivity reaction. It resolves with or without stopping or reducing the 
dose of lithium and with the treatment of topical applicants. 
 
Lihtium and Acne, Acneiform eruption: 
Acneiform eruptions are papulopustular, nodular or cystic dermatosis which usually lack 
comedones.  
Kusumi in1971 reported a patient who had developed acneiform eruption within few days of 
starting lithium therapy. It resolved on discontinuing lithium. They again developed acneiform 
eruptions on reinstitution of lithium. Case reports by Oei and bour, 1978 show that lithium is 
found to exacerbate pre-existing acne. 
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Yoder in 1975 described acneiform eruptions due to lithium. Acneiform eruptions are 
characterized by monomorphic pustules on an erythematous base. Most commonly it occurs in 
the extremities. Histological examination of severe acneiform eruptions over the extremities 
reveals they were suggestive of folliculitis. (14)       
 
Aldoroty and Levine had described a patient on lithium that developed an acneiform eruptions 
over face .It occurs after 2 weeks of lithium therapy with serum lithium level of 0.5-0.6 me/l. 
lesions were treated with minocyclin and tetracycline despite worsening occurred.  Improved on 
reduction of dosage and completely remitted on stoppage of lithium.  
 
Naveen Kansal had described the mechanism under which lithium causes skin reaction. They 
postulated that lithium causes alteration in the calcium homeostasis by modulating the second 
messenger system such as adeny cyclase and inostol monophosphatase pathways. The resulting 
lower intracellular calcium levels leads to increased proliferation of keratinocytes and increases 
the inflammatory reactions of polymorphonuclear leukocytes. Acneform eruptions usually 
cleared with the use of topical retinoids(15). 
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Lithium and Psoriasis:  
Psoriasis are chronic cutaneous problem characterized by thick white silvery or red patches, 
which most often appears on the knees, elbows, scalp, extremities or lower back. 
The association of lithium with psoriasis was described by carter in 1972.The incidence of 
lithium induced psoriasis has reported to be 1.8 to 6%. Lithium causes exacerbation of pre-
existing psoriasis, triggers psoriasis in no family or past history of psoriasis and induces psoriasis 
in unaffected area of psoriatic patients. 
 
Bakker and Pepplinkhuizer et al in 1976 had described case reports on psoriasis and its 
association with lithium.  23 cases were reported of which 13 had pre-existing psoriasis and 
family history of psoriasis. They reported that after initiating lithium therapy, pre-existing 
psoriasis was aggravated and the response to previous effective treatment had become poor. 15 
cases were reported to have developed psoriasis for the first time after initiating lithium therapy. 
(12) 
In a case report in 2006, a 60 years old female had developed a red maculopapular rash within 6 
days of initiation of lithium therapy. Serum lithium level was found to be within therapeutic 
range. Females are more prone to develop psoriatic lesions and were usually within the first year. 
In this case they temporally correlated the duration of therapy and the onset of rash. (11, 16)    
 
Studies shows patient develops psoriatic lesions on therapeutic serum lithium level (17). The 
relationship with the dose of lithium and the appearance of psoriasis is not yet clear.  Most of the 
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studies have noticed that there is no relationship with the dose of lithium and the appearance of 
psoriasis (18). But few study reports a dose-dependent relationship of lithium and development of 
psoriasis. (19) 
 
The latency period between the development of psoriatic lesions and the initiation of lithium 
treatment ranges from a weeks to several months (20).These latency periods are classified as short 
(< 4 weeks), medium (4 weeks- 12 weeks) and long (> 12 weeks). The latency period is shorter 
for exacerbation of pre-existing psoriasis than for induction of new psoriasis.  
 
The clinical manifestation of lithium induced psoriasis and idiopathic psoriasis are similar. The 
most common manifestation is plaque type lesions mostly in the scalps which gradually spreads 
to the trunk and extremities and are mostly resistant to treatment. But other manifestations are 
generalized psoriasis, pustular psoriasis, palmoplantar pustulosis,  erythroderma, non specific 
psoriasiform dermatitis,  scalp psoriasis,finger nail abnormality, psorasiform dermatitis and 
psoriatic arthropathy(21). Psoriatic nails are characterized by the yellow, opaque, roughening and 
pitting of nails.  
 
The mechanism of lithium induced psoriasis is not known. Lithium causes decrease in cyclic 
adenosine monophosphate which results in low levels of intracellular calcium leads to increased 
proliferation of keratinocytes, affect terminal differentiation, enhanced chemotaxis, and 
phagocytic activity of leukocytes (22, 23). 
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Another hypothesis is that “inositol depletion hypothesis” that lithium causes depletion of 
inositol monophosphatase results in lower level of intracellular calcium.  This is evident by the 
supplementation of inositol reverses the psoriasis caused by lithium. 
 Recent studies shows that lithium is involved in cytokine dysregulation (interleukin 2, tumor 
necrotic factor alpha and interferon beta) and it may play an important role in the pathogenesis of 
psoriasis.  
Recent studies showed that inositol use in treating lithium induced psoriasis. Dietary inositol 
does not cross the blood brain barrier and does not affect the effect of lithium as mood stabilizers 
(24). It is evidenced by improvement in the Psoriasis Area and severity index (PASI) scale.  
Another study showed that omega -3-fatty acid of around 6g/day was useful in acute lithium 
induced psoriasis (25). 
Lithium induced psoriasis are resistent to treatment and are managed with topical steroids, 
vitamin D analogues, oral retinoids, PUVA (psoralen and ultraviolet A) therapy, and 
methotrexate(26).Even treatment resistant psoriasis warrants change of mood stabilizers 
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Lithium and systemic lupus erythematosis: 
Systemic lupus erythematosis is a chronic inflammatory disease that has relapsing and remitting 
course. 
Antonov et al had described that lithium is suggested to induce lupus erythematosis. Lithium 
induced lupus was more common among females and among adolescence (20-40 years). The 
mechanism of lithium induced SLE is not yet clear (27). 
Cell mediated immunity is affected in systemic lupus erythematosis. The blood sample of SLE 
patients was found to have low interleukin 2 level and these low levels correlated with the 
severity of illness. Study showed that in vitro incubation of T-cells with lithium augment 
interleukin-2 production. Lithium is believed to increase the cytosol inositol triphosphate level 
and   increase impaired intracellular transduction in T cells. 
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Lithium and alopecia: 
Orwin 1983, Mc Creadie and Morrison 1985, reported 2 case studies in which they had 
described 12-17% of patient’s complaints of hair loss most commonly among females (28). They 
had described that hair loss to be occurring within 4 months of starting lithium therapy and hair 
loss is reversible on withdrawal of lithium. In some studies it is reported to have 12-19% hair 
loss. (29)  
Yassa and Ananth 1983, they had described evidences for the reversibility of hair loss on 
withdrawal of lithium. Controversial reports in Some studies states that hair fall subsides even 
during the course of lithium therapy (30).Jefferson et al 1979,  had demonstrated the cause/ effect 
relationship, where rechallenging of lithium therapy causes hair loss . 
 
Mortimer and Dawber et al had described that hair loss occurs within therapeutic range of 
lithium therapy.  
The exact etiologies for hair loss are unknown. It has been hypothesized that lithium gets 
concentrate in the hair follicles. It affects both the growth and size of the hair. But no pathology 
was found in hair samples on electron microscopy.  Other hypothesis are hypothyroidism occurs 
during lithium therapy are known to cause hair loss. Causal relationship has been associated with 
hair loss and hypothyroidism. But still has not been proven yet. Monitoring thyroid function test 
is necessary .Corrections of thyroid status results in reversibility of alopecia (31, 32, and 33). 
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A three year follow up study on lithium cases reported about 12% incidence of alopecia (34).23% 
reported their hair to become straighter and 19% to have thinning of hair. It causes alopecia 
usually within 4-6 months period of lithium therapy. Vestergaard p et al in 1980 described that 
Scarcity of all body hair occurs if the person had pre-existing alopecia areata. 
Reports were also found on combination of both hair loss and severe acneiform eruptions due to 
lithium carbonate. It occurred during a period of 3 months of therapy 
 
Lithium and folliculitis: 
Folliculitis is defined based on the histological features with the presence of inflammatory cells 
within the hair follicle creating follicular based pustules. 
Lithium induced folliculitis are usually asymptomatic and are distributed in the extensor surface 
of the forearm and is due to inflammatory reaction. It occurred after longer duration of lithium 
and resolved spontaneously even with the therapy. Histological reports revealed follicular 
dilatation with chronic inflammatory infiltrate around the peri-follicular region. 
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In1983, Sarantidis et al, in his study he had compared both lithium treated patients with the 
control groups who were on non-neuroleptics. He had described the patients who developed 
cutaneous conditions because of the lithium or exacerbated due to lithium as secondary 
cutaneous condition. 
 
 
In this study they had described that psoriasis and acneiform eruptions were the most common 
among cutaneous conditions.No significant differences were noted in age among the lithium and 
the control group. No significant differences were found in the dose, duration of lithium therapy 
and among family and past history of cutaneous reactions. Females were more common to report 
secondary cutaneous conditions 
 
Indian studies:  
 Mohandas et al in his study described the various cuaneous side effects of lithium therapy and 
the mechanism with which it causes skin reaction. He described the prevalence of alopecia to be 
12-19% and occurs on prolonged treatment. The mechanism with which it occurs is not clear but 
found the lithium aggravates the cutaneous conditions causing neutrophilic infiltration.  
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Vijay Aithal ,Prakash Appaih in 2015, had described a patient on lithium who developed both  
acne conglobata and hidradenitis suppurativa (HS). Hidradenitis suppurativa and acne 
conglobata are rare manifestations with only 3 case reports described so far. In all 3 cases, the 
serum lithium levels were within the therapeutic range. Patient had taken lithium for longer than 
9 years and dose was 400mg. Initially patient had developed acneiform eruption at serum lithium 
level of 0.7meq/l and later he had developed acne conglobata at level of 0.86meq/l.  
Initially it was hypothesized that Hydradenitis suppurativa was due to involvement of apocrine 
glands. Later it was found to be due to follicular obstruction, folliculitis and cystic dilatation. It is 
also hypothesized to be caused by neutrophilic chemotaxis which induces an inflammatory 
cascade (35).Hence cutaneous side effects may not correlate with the serum lithium higher than 
therapeutic level. 
 
K.B Shreedar and et al reported a Case on lithium induced drug hypersensitivity are published in 
2015. Lithium induced drug hypersensitivity syndrome is also called as DRESS, Drug rash with 
eosinophilia and systemic symptoms, DIDMOS – Drug induced delayed multi-organ 
hypersensitivity syndrome.  It is the most severe adverse skin reaction which is characterized by 
fever,organ involvement and skin rash. They presented with fever, generalized maculopapular 
rash, glossitis, hepatomegaly, lymphadenopathy and pedal edema within 4 weeks of therapy with 
the dose of 900mg of lithium and the serum lithium level of 1.12meq/l.It occurs as a result of 
immunologically mediated reaction in genetically susceptible Individual (36).  
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AIM AND OBJECTIVE OF THE STUDY: 
1. To assess the prevalence of skin reactions in Bipolar affective disorder (BPAD) 
patients on lithium  
2. To evaluate the relationship between the dosage of lithium and cutaneous side 
effects  
3. To assess the relationship between serum lithium level and cutaneous side effect. 
4. To evaluate the duration of lithium therapy and cutaneous side effects. 
5. To assess the reduction or stoppage of dose of lithium has any change in the course 
of cutaneous side effects. 
6. To assess the course of pre-existing skin reactions, when patient is initiated with 
lithium therapy. 
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METHODOLOGY: 
We recruited both inpatient and outpatient Bipolar affective disorder patient, who were 
diagnosed based on ICD-10 (international classification of disease) criteria by a qualified 
psychiatrist and who came to psychiatry department. We recruited patients who were newly 
started or already were on lithium therapy. We recruited 52 patients by convenient sampling and 
they were followed up for 12 months. All the patients were recruited after getting written 
informed consent from the patient’s attender and if possible from the patient. If the consent could 
not be obtained from the patient during initial assessment, it was obtained during subsequent 
follow up.  
 
 
Inclusion criteria in our study are people between 18-65 years of age, BPAD patient who were 
newly started on lithium or already on lithium therapy and who gives written informed consent. 
We excluded patient on other mood stabilizers and on other medication causing skin reactions            
(ACE inhibitors, CCB-Amlodipine, diltiazem Fluconazole , Quinine, Terbinafine,   
            Paclitaxel). 
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Initial Assessment: 
 
Initial assessments were done using initial semi-structured proforma. Sociodemographic details 
such as age, sex, education status, socio-economic status was collected using a semi structure 
proforma. Socio-economic status was assessed using Modified kuppusamy’s scale. 
 
Baseline information regarding the duration of lithium therapy, dose of lithium and the serum 
lithium levels, development of cutaneous side effects was collected. Patients were divided 
arbitrarily into 3 groups based on the dose of lithium - <800mg, 800-1200mg and > 1200mg. 
They were also divided into three groups according to serum lithium level as <0.8, 0.8-1.2, 
>1.2mEq/L and based on duration of lithium therapy - <6months, 6 months -1year and > 1 year.   
 
History regarding skin lesion was obtained and physical examinations was done to check for the 
presence of skin lesions in sun light for all the patients, with the check list describing the skin 
lesions, after consulting with the dermatologist. . If the patient has any pre-existing skin lesions 
they were taken over to the dermatologist and necessary treatment were given for the lesions.  
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Follow ups: 
 
After initial assessment all the patients were followed up periodically at 4th, 8th, 12th, 16th, 20th 
and 24th weeks. After that they were followed up for once in two months at 8th, 10th and 12th 
months. At each follow up were assessed using follow up semi-structured proforma. It includes 
assessment of the dosage of lithium, serum lithium level, duration of lithium therapy and the 
development of new skin lesions. The change in the courses of pre-existing skin lesions was 
assessed. The change of lithium dose was assessed as reduced or maintained or change over to 
other mood stabilizers.  
 
During each follow ups patients were asked for any skin lesions and physical examinations was 
done. If the patient develop any new skin lesions dermatologist opinion were sought each time 
and were give oral medications and topical applicants. The course of the skin lesions were 
assessed as static, worsened or improved.  
 
 
If the patient missed a follow up they were contacted over phone and enquired for the presence 
of any skin lesions. If the patient has any skin lesions they were reinforced to come for follow 
up. 
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SAMPLE SIZE ESTIMATION: 
 
We calculated sample size by using prevalence of skin lesion in previous study which is 3- 45%. 
By keeping prevalence as 45% we calculated sample size using the following formula. 
 
                                                            N= 4PQ/ d2 
P= Prevalence (From previous study) 
Q= 100-P 
d= Allowable error (5-20% of P) 
Estimated sample size of our study is 177.We had recruited consecutive sample size within two 
and half month and followed up for 1 year. 
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STATISTICAL ANALYSIS: 
 
 Statistical analysis was conducted using soft ware package used for statistical analysis 
(SPSS) version 19.0 for windows. 
 
 We compared the prevalence of skin reaction with the following variables such as Age, 
gender, Socio economic status and education and calculated using percentage. 
 
 Mean standard deviation of lithium dose, serum lithium level and duration of lithium 
therapy was calculated and was expressed in bar diagram. 
 Prevelance of skin lesions was calculated during percentage each follows up and was 
expressed in pie-chart diagram. 
 
 Association of cutaneous lesion with dosage, serum lithium level in all follow ups was 
calculated using chi square test with statistical significance of p<=0.05. 
 Association of cutaneous lesion with lithium dose, serum lithium level, and duration was 
done using independent student t-test. 
 The course of pre-existing skin lesions was depicted graphical representation with x- axis 
denoting duration of follow up and y-axis denoting severity of illness. 
 Prevalence of individual cutaneous leions are compared with the age, sex and socio-
economic status and was calculated using percentage. 
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NO 1: FLOW CHART: 
 
                                                 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSG hospital (IP/OP) BPAD patients on 
lithium (diagnosed as per ICD 10) 
meeting inclusion and exclusion 
criteria 
Written informed consent from 
patient and relatives were obtained 
Socio-demographic profile and initial 
assessment were made for 52 
recruited patients (semi-structured 
proforma) 
 Arbitrarily divided lithium dose into 
(<800 ,800-1200, >1200) 
 Divided serum Lithium level (<0.8,0.8-
1.2,>1.2) 
 Duration of lithium therapy (6m,6-
12m,>12m) 
 Preexisting skin lesions 
 
 
Examined for skin lesion and 
dermatologist opinion obtained 
All patients were  followed up 
periodically  at 
1st,2nd,3rd,4th,5th,6th,8th,10th and 12th 
month 
Results were analyzed 
 Dose 
 Duration 
 Serum lithium 
level(Evolving 
skin lesion) 
 Preexisting 
skin lesion 
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RESULTS: 
TABLE 1:  BASELINE SOCIODEMOGRAPHIC DETAILS OF 
THE STUDY SAMPLE 
 
 
VARIABLES 
 
NUMBER OF PATIENTS (n)/ 
PERCENTAGE 
 
Age in years 
 
  < 40 years 
 
     40-60years 
   
   >60years 
 
Gender 
 
  Female 
 
  Male 
 
 
Socio-economic status 
 
 Upper middle 
 
 Lower middle 
 
 
Education 
 
 Illiterate  
 
Mid school 
 
High school 
 
Postgraduate 
 
 
 
31 (59.6%) 
 
18(34.6%) 
 
3(5.8%) 
 
 
 
25(48.1%) 
 
27(51.9%) 
 
 
 
 
49(94.2%) 
 
3(5.8%) 
 
 
 
 
15(28.8%) 
 
30(57.7%) 
 
7(13.5%) 
 
0 
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In the study sample 48.1% were females and 50.9% were males. The age groups were divided 
into less than 40years, 40-60 years and more than 60 years. 59.6% are less than 40 years, 34.6% 
are in the mid- adolescent age group and 5.8% are in the age group of more than 60 years.  
 
Most of them had finished mid school level (6th-10th standard) of education (57.7%).  28.8% are 
illiterate and 13.5% are high school (10th-12th standard).94.2% of the study sample were from 
upper middle SES and 5.8% from lower middle socio-economic status. 
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FIGURE 1: 
 
 
 
 
Total prevalence of lithium induced skin reactions are 38.46%. 
 
 
 
 
38.46%
61.54%
PREVALENCE OF LITHIUM INDUCED 
CUTANEOUS SIDEEFFECTS
prevalence of skin lesion
Total no of patient without skin
reaction
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DROPOUTS: 
After recruitment of 52 patients, 10 were dropped out at the end of the study. Of which five were 
dropped out because of poor compliance. One dropped out within few days of recruitment as 
they developed lithium toxicity. One dropped out at the end of 3rd month due to persistent 
vomiting and he was changed over to another mood stabilizer. One dropped out at the end of 5th 
month as they are not affordable to do routine serum lithium level. Of the 10 drop outs, one had 
dropped out due to severe skin lesions due to lithium therapy. That case is a known case of 
systemic lupus erythematosis who had developed severe hairfall after starting lithium and they 
stopped lithium at the end of 3rd month.    
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CHART NO 2: DROPOUTS FLOW CHART: 
 
 
 
 
 
                                                                         
                                                    
 
                                                                  
          
 
 
 
 
 
 
 
 
 
 
Recruited   52 Bipolar affective 
disorder patients (ICD-10 
Criteria) 
 
 
10 were dropped out during follow 
ups 
5 Dropped out of 
poor compliance 
1 changed 
consultation 
 
1 due to lithium 
toxicity 
1 due to 
persistent 
vomiting  
 1 due to poor 
affordability to 
check serum 
lithium level 
hence changed 
to other mood 
stabilizer 
1 due to severe 
hairfall 
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Table 2: Prevalence of skin lesions during first follow up: 
 
Skin lesion  
 
Frequency (n)  
 
Percentage % 
Acneiform eruption 10 19% 
Hairfall 2 3.8% 
Seborrheic dermatitis 1 1.9% 
Acne & hyperpigmentation 1 1.9% 
lithium induced ulcer 1 1.9% 
Acne & hairfall 1 1.9% 
 
 
During first follow up 10 had developed acneiform eruption, 2 had hairfall, 1 had combined acne 
and hyperpigmentation, and 1 had combined acne and hairfall, 1 had seborrheic dermatitis and 1 
had lithium induced ulcers.  
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Table 3: Prevalence of skin lesions during second follow up: 
 
Skin lesion  
 
Frequency (n)  
 
Percentage % 
Acneiform eruption 11 20% 
Hairfall 4 7.7% 
Seborrheic dermatitis 1 1.9% 
Acne, hyperpigmentation 1 1.9% 
lithium induced ulcer 1 1.9% 
Acne & hairfall 1 1.9% 
 
 
During second follow up, 11 had developed acneiform eruption, 4 had hairfall, 1 had combined 
acne and hyperpigmentation, and 1 had combined acne and hairfall, 1 had seborrheic dermatitis 
and 1 had lithium induced ulcers 
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Table 4: Prevalence of skin lesions during third follow up: 
 
 
Skin lesion  
 
Frequency (n)  
 
Percentage % 
Acneiform eruption 10 19% 
Hairfall 4 7.7% 
Hyperpigmentation 1 1.9% 
lithium induced ulcer 1 1.9% 
 
 
During third follow up, 9 had developed acneiform eruption, 4 had hairfall, 1 had combined acne 
and hyperpigmentation, and 1 had hyperpigmentation and 1 had lithium induced ulcers. 
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Table 5: Prevalence of skin lesions during fourth follow up: 
 
Skin lesion  
 
Frequency (n)  
 
Percentage % 
Acneiform eruption 7 13.3% 
Hairfall 6 11.4% 
Hyperpigmentation 1 1.9% 
lithium induced ulcer 1 1.9% 
Acne & hairfall 1 1.9% 
 
 
 
During fourth follow up, 7 had developed acneiform eruption, 6 had hairfall, 1 had combined 
acne and seborrheic dermatitis, and 1 had hyperpigmentation and 1 had lithium induced ulcers. 
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Table 6: Prevalence of skin lesions during fifth follow up: 
 
Skin lesion  
 
Frequency (n)  
 
Percentage % 
Acneiform eruption 4 7.6% 
Hairfall 5 9.5% 
Hyperpigmentation 2 3.8% 
lithium induced ulcer 1 1.9% 
Acne & hairfall 1 1.9% 
 
 
During fifth follow up, 4 had developed acneiform eruption, 5 had hairfall, 1 had combined acne 
and seborrheic dermatitis, and 2 had hyperpigmentation and 1 had lithium induced ulcers. 
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Table 7: Prevalence of skin lesions during sixth follow up: 
 
 
Skin lesion  
 
Frequency (n)  
 
Percentage % 
Acneiform eruption 6 11.5% 
Hairfall 4 7.7% 
Hyperpigmentation 2 3.8% 
lithium induced ulcer 1 1.9% 
 
During sixth follow up, 6 had developed acneiform eruption, 4 had hairfall, and 2 had 
hyperpigmentation and 1 had lithium induced ulcers. 
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Table 8: Prevalence of skin lesions during seventh follow up: 
 
Skin lesion  
 
Frequency (n)  
 
Percentage % 
Acneiform eruption 5 11.5% 
Hairfall 4 7.7% 
Seborrheic dermatitis 1 1.9% 
Hyperpigmentation 2 3.8% 
lithium induced ulcer 1 1.9% 
Acne &  seborrheic dermatitis 1 1.9% 
 
During seventh follow up, 5 had developed acneiform eruption, 4 had hairfall, and 2 had 
hyperpigmentation, 1 had lithium induced ulcers, 1 had combined lithium with seborheic 
dermatitis and 1 had seborrheic dermatitis. 
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Table 9: Prevalence of skin lesions during eight follow up: 
 
 
Skin lesion  
 
Frequency (n)  
 
Percentage % 
Acneiform eruption 3 5.8% 
Hairfall 4 7.7% 
Seborrheic dermatitis 1 1.9% 
Hyperpigmentation 2 3.8% 
lithium induced ulcer 1 1.9% 
Acne &  seborrheic dermatitis 1 1.9% 
 
During eighth follow up, 3 had developed acneiform eruption, 4 had hairfall, and 2 had 
hyperpigmentation, 1 had lithium induced ulcers, 1 had combined lithium with seborheic 
dermatitis and 1 had seborrheic dermatitis. 
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Table 10: Prevalence of skin lesions during ninth follow up: 
 
 
 
Skin lesion  
 
Frequency (n)  
 
Percentage % 
Acneiform eruption 1 1.9% 
Hairfall 7 13.3% 
Seborrheic dermatitis 1 1.9% 
Hyperpigmentation 2 3.8% 
lithium induced ulcer 1 1.9% 
Acne & seborrheic dermatitis 1 1.9% 
 
 
During eighth follow up, 1 had developed acneiform eruption, 7 had hairfall, and 2 had 
hyperpigmentation, 1 had lithium induced ulcers, 1 had combined lithium with seborheic 
dermatitis and 1 had seborrheic dermatitis. 
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TABLE 11: PREVALENCE OF CUMULATIVE SUBTYPE OF 
SKIN LESIONS: 
 
 
 
S.NO Type of skin lesion Initial F1 F2 F3 F4 F5 F6 
 
1 
 
Acneiform eruption 
 
7(13.3%) 
 
10(19%) 
 
11(20%) 
 
9(17.3%) 
 
7(13.3%) 
 
4(7.6%) 
 
6(11.5%) 
 
2 
 
Hairfall 
 
1(1.9%) 
 
2(3.8%) 
 
4(7.7%) 
 
4(7.7%) 
 
6(11.4%) 
 
5(9.5%) 
 
4(7.7%) 
 
3 
 
Seborrheic dermatitis 
 
0 
 
1(1.9%) 
 
1(1.9%) 
 
0 
 
0 
 
0 
 
0 
 
4 
 
Hyperpigmentation 
 
0 
 
0 
 
0 
 
1(1.9%) 
 
1(1.9%) 
 
2(3.8%) 
 
2(3.8%) 
 
5 
 
Acne & 
Hyperpigmentation 
 
1(1.9%) 
 
1 (1.9%) 
 
1 (1.9%) 
 
1(1.9%) 
 
0 
 
0 
 
0 
 
6 
 
Lithium induced ulcer 
 
0 
 
1(1.9%) 
 
1(1.9%) 
 
1(1.9) 
 
1(1.9%) 
 
1(1.9%) 
 
1(1.9%) 
 
7 
 
Acne & Hairfall 
 
0 
 
1(1.9%) 
 
1(1.9%) 
 
0 
 
0 
 
0 
 
0 
 
8 
 
Acne & seborrheic 
dermatitis 
 
0 
 
0 
 
0 
 
0 
 
1(1.9%) 
 
1(1.9%) 
 
0 
 
 
Baseline prevalence of cumulative subtype of skin lesions: 
 
During initial recruitment 9 patients had developed skin lesions. During initial assessment 7 had 
developed acneiform eruptions, 1 had developed hairfall and 1 had combined type acneiform 
eruptions and hyperpigmention. 
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TABLE 12: PREVALENCE OF CUMULATIVE SUBTYPE OF 
SKIN LESIONS: 
 
 
 
S.NO 
 
Type of skin lesion 
 
F7 
 
F8 
 
F9 
 
1 
 
Acneiform eruption 
 
5(9.6%) 
 
3(5.8) 
 
1 (1.9%) 
 
2 
 
Hairfall 
 
4(7.7%) 
 
4(7.7%) 
 
7(13.3%) 
 
3 
 
Seborrheic dermatitis 
 
1(1.9%) 
 
1(1.9%) 
 
1(1.9%) 
 
 
4 
 
Hyperpigmentation 
 
2 (3.8%) 
 
2 (3.8%) 
 
2 (3.8%) 
 
5 
 
Acne & 
Hyperpigmentation 
 
0 
 
0 
 
0 
 
6 
 
Lithium induced ulcer 
 
1(1.9%) 
 
1(1.9%) 
 
1(1.9%) 
 
7 
 
Acne & Hairfall 
 
0 
 
0 
 
0 
 
8 
 
Acne & seborrheic 
dermatitis 
 
1(1.9%) 
 
1(1.9%) 
 
1(1.9%) 
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ANALYSIS OFCUMULATIVE PREVALENCE OF SKIN 
LESIONS DURING 1 YEAR FOLLOW UP: 
We have looked for the prevalence of individual skin lesion and its outcome with treatment 
during 1 year follow-up. 
 An Acneiform eruption has increased from baseline to 2nd and 3rd follow up and has 
gradually reduced at the end of 1 year from 19% to 1.9%.   
 Hairfall has increased from baseline to the end of 1 year from 1.9% to 7.7%. 
 1.9% has developed seborrheic dermatitis at 2nd and 3rd follow up which has cleared at 
the end of 6th follow up and again reoccurred at the end of 1 year in 1.9%. 
 Hyperpigmentation has  developed during 3rd follow up and has increased at the end of 1 
year from 1.9% to 3.8% 
 Combined acne with hyperpigmentation has developed in 1.9% from baseline to 3rd 
follow up and has cleared during further follow ups. 
 Lithium induced ulcer has developed in 1st follow up and persisted throughout. It has 
developed in the right index and middle fingers with multiple ulcers gradually it has 
increased its size and number of ulcers during each follow up. But after the end of the 
study, lithium was stopped and was changed over to other mood stabilizers. 
  Combined acneiform eruptions and hairfall has occurred in 1.9% during 1st and 2nd 
follow up and thereafter cleared at the end of the study. 
 Combined acneiform eruption and seborrheic dermatitis has occurred in 1.9% in the4th 
and 5th follow up and cleared at the end of the study. 
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TABLE 13: PREVALENCE OF LITHIUM INDUCED SKIN 
REACTION AMONG VARIOUS DOSES OF LITHIUM: 
FOLLOW UP <800 mg 800-1200 mg  1200 mg X2 
Initial 2/20           10% 8/26          30.8% 2/6            33.3% 0.207 
Follow up 1 1/14           7.1% 4/27         14.8% 3/8            37.5% 0.171 
Follow up 2 1/12           8.3% 4/27         14.8% 3/8            37.5% 0.338 
Follow up 3 2/10          20.0% 5/26         19.2% 4/9            44.4% 0.156 
Follow up 4 1/7            14.3% 4/25          16% 3/8            37.5% 0.530 
Follow up 5 1/7            14.3% 5/24          20.8% 1/7            14.3% 0.923 
Follow up 6 1/7            14.3% 6/23          26.1% 1/7            14.3% 0.801 
Follow up 7 1/7            14.3% 6/22          27.3% 2/8            25% 0.845 
Follow up8 2/16          12.5% 3/17          17.6% 2/4            50% 0.353 
Follow up 9 1/7            14.3% 3/22          13.6% 1/8            12.5% 0.983 
 
Prevalence of lithium induced skin lesions is not statistically significant comparing with varying 
dose. 
 
 
 
54 
 
FIGURE 2: COMPARISON OF SKIN LESIONS BETWEEN 
THREE GROUPS OF DOSES 
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FIGURE 3: COMPARISON OF SKIN LESIONS BETWEEN 
THREE GROUPS OF DOSES  DURING LAST THREE FOLLOW 
UPS: 
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TABLE 14: PREVALENCE OF LITHIUM INDUCED SKIN 
REACTION AMONG VARIOUS SERUM LITHUM LEVELS: 
 
 
 
Follow ups <0.8 meq/L 0.8-1.2 meq/L > 1.2 meq/L X2 
Initial 3/25          12.0% 8/20          40.8% 1/7            14.3% 0.072 
Follow up 1 2/21          9.5% 5/23          21.7% 1/5              20% 0.534 
Follow up2 2/20           10% 6/23          26.1% 0/5              0% 0.211 
Follow up 3 4/19          21.1% 6/22          27.3% 2/5              40% 0.681 
Follow up 4 1/16           6.3% 6/20           30% 1/4              25% 0.319 
Follow up5 1/15           6.7% 4/19          21.1% 2/4              50% 0.219 
Follow up 6 2/15          13.3% 3/17         17.6% 3/5               60% 0.139 
Follow up 7 3/16          18.8% 3/17          17.6% 3/4               75% 0.082 
Follow up 8 2/16          12.5% 3/17          17.6% 2/4               50% 0.353 
Follow up 9 1/16           6.3% 3/17          17.6% 1/4               25% 0.657 
Prevalence of lithium induced skin lesions is not statistically significant comparing with varying 
serum lithium level 
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FIGURE 4: COMPARISON OF SKIN LESIONS BETWEEN 
THREE GROUPS OF SERUM LITHIUM LEVEL 
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FIGURE 5: COMPARISON OF SKIN LESIONS BETWEEN 
THREE GROUPS OF SERUM LITHIUM LEVEL DURING LAST 
THREE FOLLOW UPS 
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TABLE 15: PREVALENCE OF LITHIUM INDUCED SKIN 
REACTION AMONG VARIOUS DURATION OF LITHUM 
LEVELS: 
 
Prevalence of lithium induced skin lesions is statistically significant during third follow up as ( P 
value <0.043) .  
 
Follow up 
 
<6 months 
 
6months-1 year 
 
>1 year 
 
X2 
 
Initial  
 
3/16        18.8% 
 
1/5            20% 
 
8/31          25.8% 
 
0.850 
 
Follow up 1 
 
3/15        28.6% 
 
1/4             25% 
 
4/30          13.3% 
 
0.754 
 
Follow up 2 
 
4/14        28.6% 
 
1/5             20% 
 
3/29          10.3% 
 
0.316 
 
Follow up 3 
 
4/13         30.8% 
 
3/4              75% 
 
5/29          17.2% 
 
0.043 
 
Follow up 4 
 
5/14         35.7% 
 
0/1               0% 
 
3/25            12% 
 
0.293 
 
Follow up 5 
 
2/12          16.7% 
 
0/1              0% 
 
5/25          20.0% 
 
0.914 
 
Follow up 6 
 
3/11          27.3% 
 
0/1                0% 
 
5/25             20% 
 
0.848 
 
Follow up 7 
 
3/11          27.3% 
 
0/1                0% 
 
6/25             24% 
 
0.873 
 
Follow up 8 
 
3/11          27.3% 
 
0/1                 0% 
 
4/25             16% 
 
0.772 
 
Follow up 9 
 
2/11          18.2% 
 
0/1                0% 
 
3/25             12% 
 
0.902 
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No significance has noticed in all other follow ups comparing with varying duration of lithium 
therapy. 
FIGURE 6: COMPARISON OF SKIN LESIONS BETWEEN 
THREE GROUPS OF DURATION OF LITHIUM THERAPY 
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FIGURE 7: COMPARISON OF SKIN LESIONS BETWEEN 
THREE GROUPS OF DURATION OF LITHIUM THERAPY 
DURING LAST THREE FOLLOW UPS 
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TABLE 16: MEAN LITHIUM DOSE, DURATION AND SERUM 
LITHIUM LEVEL WITH LITHIUM INDUCED SKIN 
REACTION DURING 1ST MONTH: 
 
 
 
Follow up 1 
 
 
Mean value 
 
 
Standard deviation  
 
 
Dose of lithium 
 
 
1150 
 
 
 
 
297 
 
 
Serum lithium level 
 
 
0.94 
 
 
0.19 
 
 
 
Duration of lithium 
therapy 
 
15.2 
 
13 
 
 
Mean value of lithium dose, serum lithium level and duration calculated during 1st month. 
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TABLE 17: MEAN LITHIUM DOSE, DURATION AND SERUM 
LITHIUM LEVEL WITH LITHIUM INDUCED SKIN 
REACTION DURING 2nd MONTH: 
 
 
 
Follow up 2 
 
 
Mean value 
 
 
Standard deviation  
 
 
Dose of lithium 
 
 
1125 
 
 
 
 
319 
 
 
Serum lithium level 
 
 
0.9 
 
 
0.15 
 
 
 
Duration of lithium 
therapy 
 
11.75 
 
10.49 
 
Mean value of lithium dose, serum lithium level and duration calculated during 2nd month. 
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TABLE 18:MEAN LITHIUM DOSE, DURATION AND SERUM 
LITHIUM LEVEL WITH LITHIUM INDUCED SKIN 
REACTION DURING 3rd MONTH: 
 
 
 
Follow up 3 
 
 
Mean value 
 
 
Standard deviation  
 
 
Dose of lithium 
 
 
1050 
 
 
 
 
320.5 
 
 
Serum lithium 
level 
 
 
0.92 
 
 
0.138 
 
 
 
Duration of 
lithium therapy 
 
16.6 
 
15.2 
 
 
Mean value of lithium dose, serum lithium level and duration calculated during 3rd month. 
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TABLE 19:MEAN LITHIUM DOSE, DURATION AND SERUM 
LITHIUM LEVEL WITH LITHIUM INDUCED SKIN 
REACTION DURING 4rd MONTH: 
 
 
 
Follow up 4 
 
 
Mean value 
 
 
Standard deviation  
 
 
Dose of lithium 
 
 
975 
 
 
 
 
249.2 
 
 
Serum lithium level 
 
 
0.91 
 
 
0.14 
 
 
 
Duration of lithium 
therapy 
 
18.50 
 
21.4 
 
Mean value of lithium dose, serum lithium level and duration calculated during 4th month. 
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TABLE 20:MEAN LITHIUM DOSE, DURATION AND SERUM 
LITHIUM LEVEL WITH LITHIUM INDUCED SKIN 
REACTION DURING 5th MONTH: 
 
 
 
Follow up 5 
 
 
Mean value 
 
 
Standard deviation  
 
 
Dose of lithium 
 
 
971 
 
 
 
 
314.7 
 
 
Serum lithium 
level 
 
 
0.86 
 
 
0.13 
 
Duration of 
lithium therapy 
 
36.7 
 
41.2 
 
 
Mean value of lithium dose, serum lithium level and duration calculated during 5th month. 
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TABLE 21:MEAN LITHIUM DOSE, DURATION AND SERUM 
LITHIUM LEVEL WITH LITHIUM INDUCED SKIN 
REACTION DURING 6th MONTH: 
 
 
 
Follow up 6 
 
 
Mean value 
 
 
Standard deviation  
 
 
Dose of lithium 
 
 
1000 
 
 
 
 
302.3 
 
 
Serum lithium 
level 
 
 
0.85 
 
 
0.12 
 
Duration of 
lithium therapy 
 
33.7 
 
39.7 
 
 
Mean value of lithium dose, serum lithium level and duration calculated during 6th month. 
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TABLE 22:MEAN LITHIUM DOSE, DURATION AND SERUM 
LITHIUM LEVEL WITH LITHIUM INDUCED SKIN 
REACTION DURING 8th MONTH: 
 
 
 
Follow up 7 
 
 
Mean value 
 
 
Standard deviation  
 
 
Dose of lithium 
 
 
1000 
 
 
 
 
282.8 
 
 
Serum lithium 
level 
 
 
0.86 
 
 
0.12 
 
Duration of 
lithium therapy 
 
33.5 
 
37.7 
 
 
Mean value of lithium dose, serum lithium level and duration calculated during 8th month. 
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TABLE 23:MEAN LITHIUM DOSE, DURATION AND SERUM 
LITHIUM LEVEL WITH LITHIUM INDUCED SKIN 
REACTION DURING 10th MONTH: 
 
 
 
Follow up 8 
 
 
Mean value 
 
 
Standard deviation  
 
 
Dose of lithium 
 
 
1028 
 
 
 
 
269 
 
 
Serum lithium 
level 
 
 
0.87 
 
 
0.13 
 
Duration of 
lithium therapy 
 
35.14 
 
43.32 
 
 
Mean value of lithium dose, serum lithium level and duration calculated during 10th month. 
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TABLE 24:MEAN LITHIUM DOSE, DURATION AND SERUM 
LITHIUM LEVEL WITH LITHIUM INDUCED SKIN 
REACTION DURING 12th MONTH: 
 
 
 
Follow up 9 
 
 
Mean value 
 
 
Standard deviation  
 
 
Dose of lithium 
 
 
1000 
 
 
 
 
316.2 
 
 
Serum lithium 
level 
 
 
0.87 
 
 
0.16 
 
Duration of 
lithium therapy 
 
45.6 
 
49.9 
 
 
Mean value of lithium dose, serum lithium level and duration calculated during 12th month. 
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TABLE 25: MEAN LITHIUM DOSE, DURATION AND SERUM 
LITHIUM LEVEL WITH LITHIUM INDUCED SKIN 
REACTION: 
 
 
 
Follow ups 
 
Skin lesion 
 
Lithium characteristics 
 
Significance 
 
Follow up 1 
 
Present: 8 
Absent: 41 
 
Mean dose:1150 (297) 
 
Mean SLL: 0.94(0.13) 
 
Mean duration: 15.25( 0.19) 
 
P=0.507 
 
P=0.601 
 
P=0.016 
 
Follow up 2 
 
Present :8 
Absent: 40 
 
Mean dose:1125 (319.5) 
 
Mean SLL: 0.93(0.15) 
 
Mean duration:11.7(10.4) 
 
P=0.933 
 
P=0.238 
 
P=0.011 
 
Follow up 3 
 
Present :12 
Absent: 34 
 
Mean dose: 1050(320.5) 
 
Mean SLL: 0.92(0.13) 
 
Mean duration: 16.6(15.2%) 
 
P=0.895 
 
P=0.105 
 
P=0.005 
 
Follow up 4 
 
Present: 8 
Absent: 33 
 
Mean dose: 975(249.2) 
 
Mean SLL: 0.91(0.14) 
 
Mean duration:18.5(21.4) 
 
P=0.226 
 
P=0.16 
 
P=0.06 
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TABLE 26: MEAN LITHIUM DOSE, DURATION AND SERUM 
LITHIUM LEVEL WITH LITHIUM INDUCED SKIN 
REACTION: 
 
 
 
 
Follow up 
 
 
Skin lesion 
 
 
Lithium characteristics 
   
 
Significance 
 
Follow up 5 
 
Present: 7 
Absent: 32 
 
Mean dose: 971(314.7) 
 
Mean SLL: 0.8(0.13) 
 
Mean duration:36.7(41.2) 
 
P=0.85 
 
P=0.20 
 
P=0.46 
 
Follow up 6 
 
Present: 8 
Absent:30 
 
Mean dose: 1000(302.3) 
 
Mean SLL: 0.85(0.12) 
 
Mean duration:33.7(37.7) 
 
P=0.71 
 
P=0.115 
 
P=0.404 
 
Follow up 7 
 
Present: 9 
Absent:29 
 
Mean dose: 1000(282.8) 
 
Mean SLL: 0.86(0.12) 
 
Mean duration:33(37.7) 
 
P=0.434 
 
P=0.068 
 
P=0.315 
 
Follow up 8 
 
Present: 7 
Absent:31 
 
Mean dose: 1028(269.0) 
 
Mean SLL: 0.87(0.139) 
 
Mean duration: 35.1 (43.3) 
 
P=0.369 
 
P=0.200 
 
P=0.636 
 
Follow up 9 
 
Present: 5 
Absent:33 
 
Mean dose: 1000(316.2) 
 
Mean SLL: 0.87 (0.16) 
 
Mean duration: 5(45.6) 
 
P=0.723 
 
P=0.447 
 
P=0.982 
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ANALYSIS OF CLINICAL PARAMETERS OF LITHIUM 
(DOSAGE, DURATION,SERUM LITHIUM LEVELS) WITH 
SKIN LESIONS: 
 
Prevalence of course of lithium induced cutaneous reactions were compared with the dose,serum 
lithium level and durations during each follow ups and are not statistically significant. 
 
So we consider taking the mean value of lithium dose, serum lithium level and duration and 
compared with the presence or absence of skin reaction during each follow up. 
 
The mean values of duration of lithium therapy are statistically significant during the 1st, 2nd and 
3rd follow up with 15, 11 and 16 month of duration of lithium. 
 
Hence patients who were on the longer the duration of lithium therapy (> 11months) were prone 
for lithium induced cutaneous side effects. 
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TABLE 27:  PERCENTAGE OF CUTANEOUS LESIONS  IN 
VARIOUS AGE GROUPS: 
 
 
 
 
Age 
 
Acneiform 
Eruption 
 
Hairfall 
 
Seborrheic 
dermatitis 
 
Hyperpigmentati
on 
 
Lithium 
 induced ulcer 
 
Early 
adulthood 
 
 
     11   
 
 (20%) 
 
 
    3     
 
(5.7%) 
 
 
      1 
 
   (1.9%) 
 
 
          2 
 
     (3.8%) 
 
 
    0 
 
 
Late 
adulthood 
 
 
    2 
 
  (3.8%) 
 
 
   3 
 
(5.7%) 
 
 
     0 
 
 
         1 
 
     (1.9%) 
 
 
    1 
 
 (1.9%) 
 
Geriatrics 
 
    1 
 
(1.9%) 
 
  0 
 
     0 
 
         1 
 
      (1.9%) 
 
    0 
 
 
 
Acneiform eruptions (20%) and hyperpigmentation (3.8%) are more common in early adulthood, 
where as lithium an induced ulcer has seen in late adulthood. Hairfall is equal in both early and 
late adulthood around 5.7%. 
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TABLE 28: PERCENTAGE OF CUTANEOUS LESIONS IN 
VARIOUS AGE GROUPS: 
 
 
 
 
1.9% of acneiform eruptions with hyperpigmentation occurred in geriatric age group, acne with 
hairfall (1.9%) occurred in early adulthood and Lithium with seborrheic dermatitis (1.9%) 
occurred in early adulthood. 
 
 
 
 
 
Age 
 
Acne, 
hyperpigmentation 
 
Acne, 
Hairfall  
 
Acne, 
Seborrheic 
dermatitis 
 
 
Early adulthood 
 
 
          0 
 
 
         1 
     
      (1.9%) 
 
 
      1 
 
   (1.9%) 
 
Late adulthood 
 
 
          0 
 
 
         1 
 
    (1.9%) 
 
 
      0 
 
Geriatrics 
 
 
          1 
     
     (1.9%) 
 
 
        0 
 
 
      0 
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TABLE 29:  GENDER DIFFERENCES IN PREVALENCE OF 
CUTANEOUS SKIN LESIONS: 
 
 
 
 
Age 
 
Acneiform 
Eruption 
 
Hairfall 
 
Seborrheic 
dermatitis 
 
Hyperpigmentati
on 
 
Lithium 
 induced ulcer 
 
Female 
 
      6 
 
 (11.4%) 
 
   4 
 
(7.6%) 
 
  0 
 
      1 
 
(1.9%) 
 
   1 
 
(1.9%) 
 
Male 
 
     8 
 
(15.2%) 
 
   2 
 
(3.8%) 
 
    1 
 
   (1.9%) 
 
    2 
 
(3.8%) 
 
0 
 
 
 
 15.2% Acneiform eruptions occurred in male and 11.4% occurred in females. 
 7.6% hairfall occurred in females and 3.8% in males  
 1.9% case of seborrheic dermatitis occurred in males. 
 3.8% males had developed hyperpigmentation and 1.9% developed in females. 
 1.9% female had developed lithium induced ulcers. 
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TABLE 30:  GENDER DIFFERENCES IN PREVALENCE OF 
CUTANEOUS SKIN LESIONS: 
 
 
 
 
 
3.8% females had developed acneiform with hairfall where as acneiform eruption with 
hyperpigmentation (3.8%) and seborrheic dermatitis (1.9%) occurred in males. 
 
 
 
 
 
 
Sex 
 
Acneiform 
Hyperpigmentation 
 
Acneiform, 
Hairfall  
 
Acneiform, 
Seborrheic 
dermatitis 
 
Female 
 
 
       0 
 
 
      2 
 
    (3.8%) 
 
 
      0 
 
Male 
     
     2 
 
 
   (3.8%) 
 
       0 
 
      1 
 
 
     (1.9%) 
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TABLE 31:  PERCENTAGE OF CUTANEOUS LESIONS 
AMONG MIDDLE SOCIO-ECONOMIC STATUS: 
 
 
 
 
SES 
 
Acneiform 
Eruption 
 
Hairfall 
 
Seborrheic 
dermatitis 
 
Hyperpigmentat
ion 
 
Lithium 
 induced ulcer 
 
Upper 
middle 
 
   12 
 
(22.8%) 
 
  3 
 
(5.7%) 
 
    1 
 
(1.9%) 
 
      2 
 
   (3.8%) 
 
0 
 
Lower 
Middle 
 
  1 
 
(1.9%) 
 
  1 
 
(1.9%) 
 
0 
 
 
 
0 
 
  1 
 
(1.9%) 
 
 
 
Most of the lesions occurred in upper middle socio-economic status. 22.8% of acneiform 
eruptions, 5.7% of hairfall, 1.9% of seborrheic dermatitis and 3.8% of hperpigmentations 
occurred in upper middle socio-economic status.1.9% of acneiform eruptions, hairfall and 
lithium induced ulcers occurred in lower middle socio-economic status. 
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TABLE 32: PERCENTAGE OF CUTANEOUS LESIONS IN 
VARIOUS SOCIO-ECONOMIC STATUS: 
 
 
 
 
1.9% of acneiform eruptions co-exist with hyperpigmentation ,hairfall and seborrheic dermatitis 
occured in upper-middle socio economic status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age 
 
Acne, 
hyperpigmentation 
 
Acne, 
Hairfall  
 
Acne, 
Seborrheic 
dermatitis 
 
Upper middle 
 
         1 
        
     (1.9%) 
 
       1 
 
  (1.9%) 
 
    1 
 
(1.9%) 
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FIGURE 8: Course of pre-existing skin lesions: 
 
 
 
 
 
 
 
 
 Tinea during recruitment has gradually subsided with treatment during 3rd month 
 SLE has developed severe hairfall at 2nd month and dropped out from the study during  
3rd month. 
  Candidiasis has gradually improved and remitted during 4th month 
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DISCUSSION 
 
Our prospective observational study was designed to find the prevalence of cutaneous 
side effects in bipolar affective disorder patients on lithium therapy. We looked for the 
relationship between the dose, serum lithium level and duration of lithium therapy and the 
cutaneous side effects. 
 
To start with, we recruited bipolar affective disorder patients who fulfilled the ICD-10 criteria, 
and who were on lithium. The mean age of our sample was 38.6 years and most common age 
group was early adulthood (18-40 years). Our sample had an equal gender distribution. Most 
were in the upper middle socio-economic status and had completed up to middle school 
3education. 
 
In our study the dropout rate was 19% . One patient  dropped out because of systemic side effect 
and 1 more due to lithium toxicity. One patient with pre-existing systemic lupus erythematosis 
dropped out due to severe hair fall. Patients with poor compliance and who were  not able to 
afford  lithium level monitoring and hence were changed to other mood stabilizers by the 
primary therapist were also considered as having dropped out. 
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 On analyzing the prevalence of lithium induced skin reactions in our study was 38.46% which 
is comparable to  the prevalence reported by Sarantidis et al and Chann et al.  
 
FIGURE 33: COMPARING OUR PREVALENCE WITH OTHER 
STUDY 
 
 
Acneiform eruption and hairfall were the most common side effects on assessing the prevalence 
of skin reaction during each follow ups. In the initial 2 months acneiform eruptions was more 
common than hairfall but during the later months ( 6th, 8th and 9th month) hairfall was found to 
have  a higher prevalence. 
38%
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  On assessing the cumulative subtype of skin reactions, Incidence of hyperpigmentation was 
noticed to be significantly higher in our study compared to previous studies. Acneiform eruptions 
and hair fall are most common lesion in our study whereas study by Sarantidis at al showed 
acneiform eruption and psoriasis as the most common secondary cutaneous lesions. 
 
The Course of acneiform eruption showed that the lesions were more during initial follow up and 
gradually improved on treatment with topical retinoids. The patients who developed this had the  
classical type of distribution over the extremities (mostly in the back of the shoulders) as 
reported in  previous studies by Jennis and Kerbs et al. 
 
 Hyperpigmentation, hairfall and seborrheic dermatitis co-exist with acneiform eruptions during 
the course. Seborrheic dermatitis has reduced along the course with treatment but reappears on 
discontinuation of treatment for the same but when compared with previous study by Dreno et al 
where lithium is used as the treatment for seborrheic dermatitis. Co-existing skin reactions are 
not discussed in previous study. 
 
In our study one patient had developed lithium induced ulcers. She had multiple small pustular 
ulcers over the index and middle fingers which was found to be most distressing for the patient. 
Even with treatment with topical applications patient continued to have repeated pustular ulcers 
in hands with fissure. 
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 Our study has shown different dosage don’t correlate statistically with lithium induced 
cutaneous side effects. The different levels of serum lithium don’t statistically correlate with 
lithium induced skin reaction.  
In our study mean duration of the lithium treatment was (11 – 15 months duration) which was 
statistically significant and has shown that longer the duration more is the occurrence of 
cutaneous side effects. But in previous study by sarantidis et al, Chann et al no significant 
association was noticed.  . 
The cutaneous adverse reactions on lithium are more common in early adulthood than in the late 
adulthood and geriatric age group and among the  subtypes of skin lesion acneiform eruptions 
are more common among males than in females which is supported by previous study by Chan et 
al. Acneiform eruptions coexists with hairfall and is more common among females. An 
acneiform eruption with hyperpigmentation is more common among males. All cutaneous 
lesions occur in upper-middle socio-economic status while lithium induced ulcer occurred in 
lower-middle socio-economic status. 
Patient with pre-existing severe skin reactions are prone for new skin reaction and may 
contribute to poor attrition. Interestingly, patients with milder skin reactions like tinea and 
candidiasis improved over the course of time. 
 
 Neither stoppage nor dose reduction was done in the patients who had developed skin reactions. 
They were also not changed over to other mood stabilizer. 
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STRENGTH: 
 
Our study is the prospective study; we had recruited the patient and followed them up for 1 year 
prospectively which is the strength of our study than in previous study they had cross sectional 
compared the patient on lithium and other psychotropic medication. 
We had assessed the relationship between the doses, duration and serum lithium level with the 
cutaneous adverse effects which is the credential of the study. 
We obtained qualified dermatologist opinion for each patient with lithium induced cutaneous 
side effects. 
Each patient were seen and assessed on nine occasions and they were encouraged to come for 
follow up if they missed. 
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LIMITATION; 
        
         Our sample size was 52 which is small to be generalized 
 
We followed up only for shorter duration of 12 months; a longer follow up would be 
more credential. 
 
We had also included few patients on lithium along with psychotropic medications which 
would also contribute to the cutaneous lesions. 
 
A single dermatologist assessing all the cohorts would have made the study better and it 
was not possible due to practical reasons. 
 
Niranjo scale which is used to assess the association between the drug induced reaction 
and drug are not used in our study. 
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No blinding was done for the primary therapist nor for the dermatologist. 
 
We followed the patients through telephonic calls which may not be correct as direct 
observation. 
 
We were unable to alter the dose of lithium or to do a serum lithium level as it was at the 
discretion of the primary therapist. 
 
Since none of the patient was stopped lithium we were unable to assess the course of skin 
lesion after stopping lithium. 
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CONCLUSION 
 
 
Prevalence of Lithium induced cutaneous lesions continuous to be high. Clinician should 
educate the patient before initiating lithium to improve the attrition rate. 
           Prevalence doesn’t vary between the dosage and the serum lithium level. Hence, Clinician  
           need not be ambivalent about reducing the dose. 
 Prevalence increases with the duration of lithium treatment, which remitted with 
treatment. Hence therapist should be cautious while treating lithium induced cutaneous 
side effects for longer duration. 
 
Lithium induced skin lesions could be managed by continuing the same dose and with 
treating the corresponding lesions as suggested by dermatologist. 
 
We would emphasize caution if patient has pre-existing severe skin lesion before 
initiating lithium therapy. 
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Xg;Gjy; gbtk; 
       Njjp: 
 
lhf;lH. Rfd;ah gphpajHrpdp  Mfpa ehd;.  gp.v];.Ip kUj;Jtf; fy;Yhhpapd; kdey 
kUj;Jtj; Jiwapd; fPo; ypj;jpak; cl;nfhs;Sk; kd vOr;rp. kdj;jsHr;rp Nehahspfspd; 
rUk vjpHtpisTfspd; ghjpg;ig mwpa Ma;T Nkw;nfhs;s  cs;Nsd;. 
Vd; Ma;T topfhl;b : lhf;lH. I. iraj; ck;kH. cjtp NguhrphpaH  
 
Ma;tpd; Nehf;fk; :. 
1. kdj;jsHr;rp kd vOr;rp. Nehahspfspd; rUk epfo;Tfis kjpg;gpLjy;  
2 ypj;jpak; msT kw;Wk; mjdhy; Vw;gLk; rUk gf;f tpisTfs; msit kjpg;gpLjy;  
3 ,uj;jj;jpy; cs;s ypj;jpak; msT kw;Wk; mjdhy; Vw;gLk; gf;f tpisTfs; msit  
  kjpg;gpLjy; 
4 ypj;jpak; rpfpr;ir fhyk; kw;Wk; rUk gf;f tpisTfis kjpg;gpLjy;  
5 ypj;jpak; msT Fiwg;G kw;Wk; epWj;Jjy; mjdhy; Vw;gLk; rUk gf;f tpisTfs;      
  msit kjpg;gpLjy;  
6 ypj;jpak; rpfpr;ir Muk;gpf;fgl;l gpd; Nehahspapd; Vw;fdNt ,Uf;Fk; Njhy;  
  vjpHtpisTfis kjpg;gpLjy; 
 
Ma;T Nkw;nfhs;Sk; ,lk; : 
 
gp.v];.Ip kUj;Jtkid. Nfhak;Gj;JhH 
 
Ma;tpd;  gyd;fs; : 
 
rUk gf;f tpisTfspd; kjpg;gPL mjdhy; tof;fkhd fz;fhzpg;G. kw;Wk; Muk;g Neha; 
fz;lwpjypdhy; kUe;J xj;JNghfhik kw;Wk; ; kdepiyghjpg;ig jtpHj;jy; 
 
ypj;jpak; Muk;gpf;fg;gl;l kdjsHr;rp. kdvOr;rp Nehahspfis 6 khj fhyj;jpw;F 
xt;nthU khjKk;. 9tJ kw;Wk; 12tJ khjk; njhlHe;J gpd;gw;wp rUk gf;f 
tpisTfspd; epfo;Tfis fhZjy;. 
VNjDk; rUk gf;f tpisTfs; Vw;gl;lhy; kdey kUj;JtH kw;Wk; Njhy; kUj;Jtuhy; 
ghpNrhjpf;fg;gLk;.  ve;j Neuj;jpy; Ntz;LkhdhYk; Ma;tpypUe;J tpyfpf;nfhs;Sk; 
chpik cq;fSf;F cz;L. 
 
Ma;tpypUe;J tpyfpf;nfhs;tjhy; cq;fSf;F mspf;fg;gLk; rpfpr;irapy; ve;j tpj 
khw;wKk; ,Uf;fhJ. 
 
,e;j Muha;r;rpf;fhf cq;fsplk; rpy Nfs;tpfs; Nfl;fg;gLk;. NkYk; ,e;j Ma;tpy; gq;F 
nfhs;tJ cq;fs; nrhe;j tpUg;gk;. ,jpy; ve;j tpjf; fl;lhaKk; ,y;iy.  ePq;fs; 
tpUg;gg;gl;lhy; ,e;j Ma;tpd; KbTfs; cq;fSf;Fj; njhpag;gLj;jg;gLk;. 
 
 
Ma;thshpd; ifnahg;gk;  : 
 
Njjp      : 
 
Ma;Tf;Fl;gLgthpd; xg;Gjy; : 
 
ehd; ,e;j Muha;r;rpapd; Nehf;fk; kw;Wk; mjd; gad;ghl;bidg; gw;wp njspthfTk;. 
Tpsf;fkhfTk; njhpag;gLj;jg;glLs;Nsd;.  ,e;j Muha;r;rpapy; gq;F nfhs;sTk;.  ,e;j 
Muha;r;rpapd; kUf;Jt hPjpahd Fwpg;Gfis tUk; fhyj;jpYk; cgNahfglgLj;jpf; 
nfhs;sTk; KO kdJld; rk;kjpf;fpNwd;.    
 
 
Ma;Tf;Fl;gLgthpd;  ngaH. Kftup  :  
 
 
 
       ifnahg;gk;    : 
 
 
    Njjp   : 
 
cldpUg;gthpd;  ifnahg;gk;  : 
 
Njjp  : 
 
Ma;thshpd; njhiyNgrp vz; : 98656 16083 
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Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
 
 
 
I , DR. B. S. Suganyapriyadharshini, am carrying out a study on the 
topic:–Incidence of cutaneous side effects with lithium therapy in BPAD 
Patients- a prospective cohort study as part of my / our research project 
being carried out under the  Department of PSYCHIATRY  
 
My  research guide is: Dr.Syed Ummar 
 
 
The justification for this study is: Lithium is considered as medication of first 
choice in BPAD patients.  Lithium is known to cause systemic side effects 
mostly but also cutaneous side effects. The purpose of the study is to evaluate 
the incidence of cutaneous side effects, whether regular monitoring, early 
diagnosis and management will help in avoiding the issue of non- compliance 
and further worsening of mood symptoms.  
 
The objectives of this study are:  
1) To assess the incidence of skin reactions in BPAD patients on 
lithium 
2) To evaluate the relationship between dosage of lithium and 
cutaneous side effects. 
3) To assess relationship between serum lithium level and 
cutaneous side effects 
4) To evaluate the duration of lithium therapy and cutaneous side 
effects 
5) To assess the reduction or stoppage of dose of lithium has any 
change in course of cutaneous side effects, in the departments of 
Psychiatry . 
6) To assess the course of pre-existing skin reactions, when patient 
is initiated with lithium therapy.  
To look for socio-demographic or other variables which may predict the 
outcome 
Sample size: 250 
 
Study volunteers / participants are (specify population group & age 
group):Patients.Age group is 18 – 60 years 
 
Location: Psychiatry department- PSGIMS&R 
 
We request you to kindly cooperate with us in this study. We propose collect 
background information and other relevant details related to this study. We will 
be carrying out:  
 
Initial interview (specify approximate duration):30-45 minutes.  
 
Data collected will be stored for a period of fifteen years. We will / will not use 
the data as part of another study. 
 
Health education sessions: Number of sessions: _____________. 
Approximate duration of each session:  
 
______________ minutes.  
 
Clinical examination (Specify details and purpose): as part of the Out patient 
procedure to look for any major co-morbidities needing hospitalized 
care(exclusion criteria) 
 
Blood sample collection: Specify quantity of blood being drawn: 
___________ml.  
 
Whether blood sample collection is part of routine procedure or for research 
(study) purpose:  Routine procedure 
 
1. Routine procedure 2. Research purpose  
 
Specify purpose, discomfort likely to be felt and side effects, if any: 
_______________________________ 
 
Whether blood sample collected will be stored after study period: Yes / No, it 
will be destroyed 
 
Whether blood sample collected will be sold: Yes / No  
 
Whether blood sample collected will be shared with persons from another 
institution: Yes / No 
 
Medication given, if any, duration, side effects, purpose, benefits:  
 
Whether medication given is part of routine procedure: Yes  
 
Whether alternatives are available for medication given: No  
 
Final interview (specify approximate duration):30-45 mts. 
 
Benefits from this study: The purpose of the study is to evaluate the incidence 
of cutaneous side effects, whether regular monitoring, early diagnosis and  
management will help in avoiding the issue of non- compliance and further 
worsening of mood symptoms.  
 
Risks involved by participating in this study: nil 
 
 
How the results will be used:  
 
If you are uncomfortable in answering any of our questions during the course of 
the interview / biological sample collection, you have the right to withdraw 
from the interview / study at anytime. You have the freedom to withdraw from 
the study at any point of time. Kindly be assured that your refusal to participate 
or withdrawal at any stage, if you so decide, will not result in any form of 
compromise or discrimination in the services offered nor would it attract any 
penalty. You will continue to have access to the regular services offered to a 
patient. You will NOT be paid any remuneration for the time you spend with us 
for this interview / study. The information provided by you will be kept in strict 
confidence. Under no circumstances shall we reveal the identity of the 
respondent or their families to anyone. The information that we collect shall be 
used for approved research purposes only. You will be informed about any 
significant new findings - including adverse events, if any, – whether directly 
related to you or to other participants of this study, developed during the course 
of this research which may relate to your willingness to continue participation. 
 
Consent: The above information regarding the study, has been read by me/ 
read to me and has been explained to me by the investigators. Having 
understood the same, I hereby give my consent to them to interview me. I am 
affixing my signature / left thumb impression to indicate my consent and 
willingness to participate in this study (i.e., willingly abide by the project 
requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal 
Representative:  
 
 
Signature of the Interviewer with date:     
 Witness: 
Contact number of PI: 9566147375 
Contact number of Ethics Committee Office:  0422 2570170Extn.: 5818 
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FOLLOWUP SEMISTRUCTURED  PROFORMA  
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SYMPTOM CHECK LIST 
 
 
1. Acne:  Lesions may be papulopustular, nodular, or cystic. While acne vulgaris typically consists of comedones. 
2. Acneiform eruptions:  (such as acneiform drug eruptions) have the same characteristic of acne but usually lack comedones. 
3. Psoriasis: Papulosquamous diseases are characterised by scaling papules (raised lesions <1 cm in diameter) and plaques (raised lesions >1 cm 
in diameter). 
4. Systemic lupus erythematosis:  
       Malar rash: Fixed erythema flat or raised over the malar eminences, tending to spare the    
      naso labial fold. 
      Discoid rash: Erythematous raised patchs with adherent keratotic scaling and follicular  
      Plugging. 
5. Alopecia 
6. Seborrheic dermatitis: Red itchy rash with white scales 
 
 
 
